Primary Fatty Acid Amide Metabolism:
Conversion of Fatty Acids and an Ethanolamine in $\text{N}_{18}\text{TG}_2$ and SCP Cells

Emma K. Farrell,§ Yuden Chen, Muna Barazanji, Kristen A. Jeffries, Felipe Cameroamortegui, and David J. Merkler*
Department of Chemistry, University of South Florida,
4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

*Corresponding author. Telephone: +1-813-974-3579 and Fax: +1-813-974-3203

E-mail address: merkler@usf.edu (D. J. Merkler)

§Present address: Department of Biochemistry, 117 Sweitzer, University of Missouri, Columbia, MO 65211, USA

Abbreviated title for Running Footline:

PFAM Metabolism in Two Mammalian Cell Lines
ABSTRACT

Primary fatty acid amides (PFAMs) are important signaling molecules in the mammalian nervous system, binding to many drug receptors and demonstrating control over sleep, locomotion, angiogenesis, and many other processes. Oleamide is the best-studied of the primary fatty acid amides, while the other known PFAMs are significantly less studied. Herein, quantitative assays were used to examine the endogenous amounts of a panel of PFAMs as well as the amounts produced after incubation of mouse neuroblastoma N18TG2 and sheep choroid plexus (SCP) cells with the corresponding fatty acids or N-tridecanoylethanolamine. Although five endogenous primary amides were discovered in the N18TG2 and SCP cells, a different pattern of relative amounts were found between the two cell lines. Higher amounts of primary amides were found in SCP cells and the conversion of N-tridecanoylethanolamine to tridecanamide was observed in the two cell lines. The data reported here show that the N18TG2 and SCP cells are excellent model systems for the study of PFAM metabolism, support a role for the N-acylethanolamines as precursors for the PFAMs, and provide valuable new kinetic results useful in modeling the metabolic flux through the pathways for PFAM biosynthesis and degradation.

Supplementary key words:

N-acylethanolamine as PFAM precursors, choroid plexus cells, N18TG2 cells, oleamide metabolism, N-fatty acylglycine oxidation, primary fatty acid amide, bioactive lipids
INTRODUCTION

Fatty acid amides have a long biological history, dating back over a century to the pioneering studies of the ceramides and sphingolipids (1,2). Primary fatty acid amides (PFAMs), R-CO-NH$_2$ with R = a long-chain fatty acid, were first identified from a biological source in 1989 with the identification of palmitamide, palmitoleamide, oleamide, elaidamide, and linoleamide in luteal phase plasma (3). At the time of their discovery, the biological function of these mammalian PFAMs was unknown. Interest in the PFAMs dramatically intensified with the discoveries that oleamide accumulated in the cerebrospinal fluid (CSF) of sleep-deprived cats, is a natural component of the CSF in the cat, rat, and human, and the administration of synthetic oleamide induced physiological sleep in rats (4). Intriguingly, later studies found that oleamide levels in the brain of the ground squirrel were ~2.5-fold higher in hibernating animals relative to that found in non-hibernating animals (5). Other functions ascribed to oleamide, since its discovery as a sleep-inducing PFAM, include the ability to modulate gap junction communication in glial cells (6,7), tracheal epithelial cells (8), seminiferous tubule cells (9), and fibroblasts (10), to allosterically activate the GABA$_A$ receptors and specific subtypes of the serotonin receptor (11-13), to effect memory processes (14), to increase food intake (15), to reduce anxiety and pain (16,17), to depress body temperature and locomotor activity (17,18), to stimulate Ca(II) release (19), and to relax blood vessels (20,21).

While much of the research regarding the PFAMs has focused on oleamide, there are studies showing that some of the other known PFAMs are bioactive. Palmitamide is a weak anticonvulsant (22), linoleamide regulates Ca(II) flux (23) and inhibits the erg current (24), and erucamide stimulates angiogenesis (25) and controls water balance (26). In addition, both mammalian phospholipase A$_2$ (PLA$_2$) and epoxide hydrolase (EH) are inhibited by series of
PFAMs with arachidonamide and \( \gamma \)-linolenamide being the most potent for the inhibition of PLA\(_2\) (27) and elaidamide being the most potent for the inhibition of EH (28). The physiological significance of the reported functions of oleamide and the other PFAMs is not completely clear as relatively high concentrations are sometimes used to elicit the indicated responses. Nonetheless, the PFAMs have emerged as an important class of mammalian cell signaling lipids. For recent reviews of PFAM metabolism, see Farrell and Merkler (29) and Ezzili \textit{et al.} (30).

The major route for PFAM degradation \textit{in vivo} is hydrolysis to the fatty acid and ammonia, a reaction catalyzed by fatty acid amide hydrolase (FAAH) (31,32). Less is definitively known about PFAM biosynthesis. One proposed route is the ammonolysis of fatty acyl-CoA thioesters (33) while a second proposed route involves the oxidative cleavage of \( N \)-fatty acylglycines (NAGs) (34,35). Mouse neuroblastoma N\(_{18}\)TG\(_{2}\) cells are known to produce oleamide (36) and, thus, must possess the enzymatic machinery necessary for oleamide biosynthesis. \( N \)-Oleoylglycine was characterized after growth of the N\(_{18}\)TG\(_{2}\) cells in the presence of an inhibitor for peptidylglycine \( \alpha \)-amidating monooxygenase (PAM) (37), supporting the hypothesis that the NAGs serve as PFAM precursors. PAM, an enzyme with a well-defined role in \( \alpha \)-amidated peptide biosynthesis (38), has been suggested to catalyze NAG cleavage \textit{in vivo}. A number of NAGs have been identified from mammalian sources (37,39) and there is evidence that these members of the fatty acid amide family are also cell signaling lipids (40-42). The biosynthesis of the NAGs is also unclear; suggested pathways include glycine conjugation of the fatty acyl-CoA thioesters (34,43) and sequential oxidation of the \( N \)-acylethanolamines (44,45) (Fig. 1).

The \( N \)-acylethanolamines (NAEs) are another branch of the fatty acid amide family of cell signaling lipids, with \( N \)-arachidonoylethanolamine (anandamide) being the most studied of
this group of molecules. Given there are multiple pathways known for the biosynthesis of the NAEs (44-46), it is likely that there are also multiple routes for the \textit{in vitro} production of the NAGs and the PFAMs (29,30). In fact, Bradshaw \textit{et al.} (46) have shown that the NAGs are produced in the C6 glioma cells via both the glycine-dependent and NAE-dependent reactions shown in Fig. 1.

The N\textsubscript{18}TG\textsubscript{2} cells produce oleamide and are known to express PAM and FAAH (36,47,48). Oleamide has been the focus of the PFAM research in the N\textsubscript{18}TG\textsubscript{2} cells and one goal of the work detailed herein was to broaden the scope of the N\textsubscript{18}TG\textsubscript{2}-based work to other PFAMs. It is essential to determine if the pathways defined for oleamide biosynthesis and degradation would account for the other known PFAMs. Our other goals were to establish the choroid plexus cells as another model system for PFAM metabolic studies and that the NAEs are precursors for the PFAMs.

We report here, for the first time, the N\textsubscript{18}TG\textsubscript{2}-mediated conversion of a series of fatty acids to PFAMs, including the production of tridecanamide from \textit{N}-tridecanoyl ethanolamine. Using the same set of fatty acids and \textit{N}-tridecanoyl ethanolamine, we report also that cultured sheep choroid plexus (SCP) cells produce PFAMs. The PFAM levels in the SCP cells were generally higher than those of the N\textsubscript{18}TG\textsubscript{2} cells, likely resulting from the lack of detectable FAAH expression in the SCP cells. The data reported demonstrate that the N\textsubscript{18}TG\textsubscript{2} and SCP cells are excellent models for the study of PFAM metabolism and provide useful indices for modeling of PFAM metabolism as the biosynthetic and degradative pathways are better defined.
MATERIALS AND METHODS

Materials and Chemicals

Linoleic acid, palmitic acid, 6-thioguanine, and fatty acid-free bovine serum albumin (BSA) were from Sigma, elaidic acid and palmitoleic acid were from Fisher, penicillin/streptomycin, EMEM, and DMEM were supplied by Mediatech Cellgro, fetal bovine serum (FBS) was from Atlanta Biologicals, BSTFA and silica were from Supelco, [\textsuperscript{2}H\textsubscript{33}]heptadecanoic acid (margaric acid, C\textsubscript{2}\textsuperscript{2}H\textsubscript{3}-(C\textsuperscript{2}H\textsubscript{2})\textsubscript{15}-COOH) was from C/D/N isotopes, goat anti-FAAH (V-17) antibody and its blocking peptide were from Santa Cruz Biotech, donkey anti-goat IgG fused to horse radish peroxidase (HRP) was from ICN Biomedical, SuperSignal chemiluminescent HRP substrate was from Bio-Rad, and MagicMark XP molecular weight markers were from Invitrogen. Mouse neuroblastoma N\textsubscript{18}TG\textsubscript{2} cells were purchased from the Deutsche Sammlung von Mikroorganism und Zellkulturen GmBH and the sheep choroid plexus cells came from the American Type Culture Collection. All other reagents and supplies were purchased from commercial sources at the highest quality available and used without further modification.

Primary Fatty Acid Amide Synthesis

PFAMs were synthesized from the acyl chloride essentially as described by Fong et al. (49). The undistilled acyl chloride was added dropwise to ice cold concentrated NH\textsubscript{4}OH at ratio of 1:6 (v/v) acyl chloride:NH\textsubscript{4}OH and the reaction allowed to proceed until the precipitation of the PFAM visibly ceased. Excess NH\textsubscript{4}OH was removed from the PFAM crystals by washing with H\textsubscript{2}O.

For most of the desired PFAMs, the required acyl chloride was available commercially. Unavailable acyl chlorides were synthesized by mixing together the free fatty acid and thionyl
chloride in a 1:2 molar ratio under N$_2$ (with stirring) and then allowing the reaction to proceed under reflux at 50 °C for 30 min. Unreacted thionyl chloride was removed by heating or by reduced pressure until gas evolution ceased.

$N$-Tridecanoylethanolamine (TDEA) was synthesized by combining triethylamine, acetonitrile, and ethanolamine in a 1.5:1:1 (v/v/v) ratio under N$_2$ at room temperature. Tridecanoyl chloride was dissolved in a minimal volume of acetonitrile, added dropwise to the ethanolamine mixture, and left to stir overnight at room temperature. The resulting solution was taken to dryness in vacuo, yielding a yellow solid. The yellow solid was dissolved in a small volume of warm ethanol and recrystallized from cold H$_2$O. After crystallization, the compound was washed with H$_2$O.

**BSA as a Fatty Acid Carrier**

BSA was used as a carrier for fatty acids in aqueous media. Fatty acids were dissolved in ethanol, converted to the sodium salt with excess NaOH, dried under vacuum, and dissolved in phosphate-buffered saline (PBS) to make a 25 mM solution. The sample was then heated in a 49 °C water bath for 5 minutes before adding 2.5 mM BSA (fatty acid free). The sample was stirred at room temperature for 4 hours, sterile-filtered, and stored at -20°C. A TDEA solution was made similarly, but an additional sonication step was added prior to addition of BSA.

**Cell Culture**

All cells were grown in 225 cm$^2$ culture dishes. The N$_{18}$TG$_2$ cells were grown in DMEM supplemented with 100 µM 6-thioguanine. The SCP cells were grown in EMEM supplemented with 100 µM sodium pyruvate. SCP and N$_{18}$TG$_2$ media had 10% FBS with 100 I.U./mL penicillin and 1.0 mg/mL streptomycin and were incubated at 37 °C with 5% CO$_2$ according to instructions from the supplier. Cultures were grown to 80%-90% confluence, the culture medium
removed, and replaced with fresh media containing 0.5% FBS and a 2.5 mM fatty acid/0.25 mM BSA mixture. After 12, 24, or 48 hr incubation, media was collected, cells washed with PBS, and detached from the flask by trypsinization. An aliquot was taken for counting on a hemacytometer with trypan blue. Cells were centrifuged and stored at -80 °C. Conditioned media was centrifuged to remove any cells and the supernatant was also stored at -80°C. The zero (0) time samples were collected without addition of the fatty acid-BSA mixture or 0.5% FBS media, but were collected in 10% FBS media under normal growing conditions. A set of control experiments were carried using cells grown in 0.5% FBS media.

**Organic Solvent Extraction of the Lipid Metabolites**

Metabolites were extracted from cells using procedures similar to those described by Sultana and Johnson (50). Methanol (4 mL) was added to the cell pellets and the resulting mixture was sonicated for 15 min at room temperature. The samples were then centrifuged to remove cellular debris and the supernatant dried under N<sub>2</sub> in a warm water bath at 40 °C. The pellet was re-extracted with 4 mL 1:1:0.1 (v/v/v) chloroform:methanol:water, sonicated for 10 min, vortexed for 2 min, and centrifuged. This second supernatant was added to the dried supernatant from the first extraction and mixture dried under N<sub>2</sub> at 40 °C. The pellet was extracted for a third time with 4.8 mL of chloroform:methanol 2:1 (v/v) and 800 µL of 0.5 M KCl/0.08 M H<sub>3</sub>PO<sub>4</sub>, sonicated for 2 min, vortexed for 2 min, and centrifuged to separate particulates from the liquid phases. The lower lipid phase from this centrifugation step was added to the dried combination of first and second supernatants and this mixture taken to dryness under N<sub>2</sub> at 40 °C.

Lipid metabolites were extracted from the conditioned media using two 15 mL washes with of chloroform:methanol 2:1 (v/v) (total extraction volume = 30 mL for this step) followed
by two washes of mixture consisting of 15 mL of chloroform:methanol 2:1 (v/v) plus 2.4 mL of 0.5 M KCl/0.08 M H$_3$PO$_4$. (the total extraction volume = 34.8 mL for this step). Precipitated protein was condensed between the aqueous and organic layers by centrifugation. The lipid-containing organic phases were combined and dried under N$_2$ at 40-50 °C or in vacuo.

**Solid Phase Extraction of the Lipid Metabolites**

Silica columns (0.5 g) were washed with n-hexane and run essentially as described by Sultana and Johnson (50). The dried lipid extracts, prepared as described above, were re-dissolved in 100 µL n-hexane and applied to a washed silica column. The mobile phase was run without positive pressure as follows: 4 mL of n-hexane, 1 mL of 99:1 (v/v) hexane:acetic acid, 1 mL of 90:10 (v/v) hexane:ethyl acetate, 1 mL of 80:20 (v/v) hexane:ethyl acetate, 1 mL of 70:30 (v/v) hexane:ethyl acetate, 1.5 mL of 2:1 (v/v) chloroform:isopropanol, and, lastly, 0.5 mL of methanol. The eluant from each different organic wash was collected separately. The eluant from the chloroform:isopropanol wash and the methanol wash were combined and taken to dryness under N$_2$ at 40-50 °C. An internal standard, 3 nmol of [${}^2$H$_{33}$]-heptadecanoic acid, was added and the mixture re-dried before derivitization.

To test effectiveness of the extraction methods, cells and media were spiked with each PFAM and subjected to the organic solvent extraction and solid phase extraction procedures before GC-MS quantification. Percent recoveries ranged from 82-101%.

**Gas Chromatography - Mass Spectrometry (GC-MS)**

All separations were performed using a Shimadzu QP-5000 GC-MS. Separations were achieved on a J & W Scientific DB-5 column (0.25 mm × 30 m) in splitless mode. The GC temperature program was 55-150 °C at 40 °C/min, hold at 150 °C for 3.6 min, ramp at 10 °C/min to 300 °C, and hold for 1 min. The transfer line was held at 280 °C and the injection
port at 250 °C throughout the separation. Helium was used as a carrier gas at a flow rate of 0.9 mL/min. The mass range detected was 35-450 amu with a scan speed of 2000. The solvent cut time was set to 7 min.

Before injection, dried samples were trimethylsilylated with 100 µL BSTFA (N,O-bis(trimethylsilyl)trifluoroacetamide). Samples were flushed with dry N₂, BSTFA added, flushed briefly again, and allowed to react at 55-60 °C for 1 hr before GC-MS analysis. The major product of PFAM derivitization was the corresponding acyl nitrile, and the PFAM-TMS was also observed. Samples were injected twice; 33.3% of the sample volume, followed by 50% of the remaining sample volume, such that 1 nmol internal sample was in each sample run. After analyzing a set of experimental samples by GC-MS (0, 12, 24 and 48 hr time intervals, each injected twice), one of the 24 or 48 hour samples was dried down, spiked with the PFAM of interest, redried, rederivitized with BSTFA, and analyzed again by GC-MS to validate PFAM and nitrile retention times.

Controls

Some PFAMs, particularly oleamide and erucamide, are used as slip additives in polyethylenes (51-53). Thus, background PFAM levels must be determined due to potential slip additive contamination. Background PFAM levels were measured by running solvents through all the same glassware and plasticware as used for the cell and media samples, and the collected solvents were subjected to sonication, solid phase extraction, and derivitization. Integration of the GC trace was taken over the same time integral as standard amides and for the same set of ions. An averaged number of cells were used to calculate blank amount of amide per cell in the blank samples. Unconditioned media was also subjected to extraction and SPE to assay for background amides.
In addition to unconditioned media and glass/plasticware, conditioned media and unconditioned media were incubated with various metabolites and tested to see if PFAMs would accumulate over time in the absence of cells. Unconditioned media was incubated with either oleamide, N-oleoylglycine, or N-oleoylethanolamine at 37 °C for 48 hr. Conditioned media was sterile-filtered with a 0.45 µm filter to remove any cells after the 48 hr incubation. The conditioned media was then incubated with oleamide, N-oleoylglycine, or N-oleoylethanolamine in BSA at 37 °C for an additional 48 hr. PFAM extraction was performed as described above.

Finally, to test for the change in oleamide production, SCP and N15TG2 cells were incubated for 48 hr with media containing 0.5% FBS and 0.25 mM BSA carrier, but no long chain fatty acyl metabolite. Cells and media were both collected and subjected to PFAM analysis as described above.

Data Analysis

Total ion chromatograms (TICs) were collected and, post-run, a set of selected ions unique to the amides and nitriles under examination was overlaid and integrated so that effects of any co-eluting compounds could be minimized. These unique ion sets are based on electron-impact (EI) fragmentation of the PFAMs and nitrile standards and can be found in Table 1. Due to the high background in the range of 17.5 – 20 minutes in the linoleic acid-incubated media, the amount of amide was calculated using the nitrile only, plotted against a standard curve of linoleonitrile from the linoleamide derivitization reaction. Similarly, endogenous oleic acid and octadecanoic acid co-eluted with palmitamide-TMS. This potentially interfering artifact was circumvented by integrating palmitonitrile only comparing these data against a standard curve of palmitonitrile. No palmitonitrile was found in cells grown in the presence of exogenously
added oleic acid, so palmitamide-TMS was not found in the oleamide spectral and could not
interfere with the quantification of oleamide. Representative chromatograms of the endogenous
oleic acid from the N\textsubscript{18}TG\textsubscript{2} cells (Fig. S1) and SCP cells (Fig. S2) are provided in the
Supplementary Material to clarify the separation and specificity.

\[ ^{2}\text{H}_{33}\text{-Heptadecanoic acid } \] was spiked into each sample as an internal standard to
measure the instrument performance. The amides and nitriles of interest were integrated along
with the \([^{2}\text{H}_{33}]\text{-heptadecanoic acid} \), both compared to their standard curves, and a correction
factor determined based on the integration of \([^{2}\text{H}_{33}]\text{-heptadecanoic acid} \). Each extraction sample
was run on the GC-MS twice, and each incubation of FFA or NAE with SCP and N\textsubscript{18}TG\textsubscript{2} cells
was done at least twice.

**Western Blot Analysis**

SDS polyacrylamide gel electrophoresis was run according to the method of Laemmli
(54). Transfer from the SDS gels onto a PVDF membrane was carried out at 80 V for 60 min.
To ensure specificity, controls were run with the FAAH antibody preincubated with its blocking
peptide prior to Western Blot analysis. Antibodies were incubated with a 50-fold molar excess
of the blocking peptide for 2.5 hours at 36 °C with agitation and this was followed by a 2-24 hr.
incubation at 4 °C in 500 µL of PBS. The antibodies were then used directly from the PBS
solution.

**RT-PCR**

N\textsubscript{18}TG\textsubscript{2} and SCP cells were isolated from culture (one T-75 cm\textsuperscript{2} flask, grown to ~90% of
confluency), lysed, and the mRNA isolated using the MicroPoly(A) Pure mRNA purification kit
from Ambion. cDNA was generated from the isolated mRNA using the RETROscript reverse
transcription kit also from Ambion. PCR conditions were as follows: an initial 3 min
denatureation at 95 °C followed by 25-45 cycles of denaturation at 95 °C (1 min), annulling at 45 °C (1 min), and elongation at 72 °C (1 min) with a final elongation cycle of 7 min at 72 °C. The PCR product was gel purified using a QIAQuick gel extraction kit (Qiagen) and the product sequenced.

RESULTS

Analysis of Background PFAMs

Endogenous amounts of the PFAMs were measured to provide a baseline reference level (time = 0), and are shown in Table 2. The levels of linoleamide, oleamide, palmitamide, palmitoleamide, and tridecanamide isolated from unconditioned media generally represent a small percentage of those isolated from conditioned media. The PFAM levels in the unconditioned media blanks were 1 - 6% of those found in media conditioned by the SCP cells and 1 - 22% of those found in media conditioned by the N18G2 cells. Linoleamide was an exception, at 44% of that measured from the N18TG2 cell conditioned media.

We also measured PFAM levels in solvents, glassware, and plasticware used in the extractions to measure background amounts from potential slip additives (51-53). PFAM levels in the solvent blanks were low, ranging between 0.5 - 8% of the amounts isolated from the SCP or N18TG2 cells. Tridecanamide was an exception as the blank value was 18% of that identified from the N18TG2 cells post-incubation.

We have divided the background PFAM levels by the average number of viable cells per experiment (with all the extraction volumes being the same) to enable a direct comparison of the background amounts to those we measured in the cells and the cell-conditioned media (Table 3). For example, 90 pmoles of palmitamide divided by the average number of viable N18TG2 cells, 7.9 × 10^7, at the start of our incubation, yields an average background palmitamide level of 12
pmoles per 10^7 N_{18}TG_2 cells (Table 3). This background level of palmitamide is \sim 1\% of the endogenous level of palmitamide from the N_{18}TG_2 cells, 930 pmoles per 10^7 N_{18}TG_2 cells.

The methods used to measure the levels of the PFAMs could not discriminate oleamide (cis-9-octadecenic acid) and elaidamide (trans-9-octadecenic acid). We have assumed that the background 18:1 amide reported here is oleamide because oleamide is a common slip additive (51,53).

**Analysis of PFAMs Produced by the N_{18}TG_2 Cells**

We first measured the amounts of linoleamide, palmitoleamide, palmitamide, and oleamide in the N_{18}TG_2 cells before growth in the presence of exogenously added fatty acids. The C18:1 PFAM identified endogenously is assumed to be oleamide rather than elaidamide. The reasons are that oleamide and not elaidamide has been identified in N_{18}TG_2 cells (36) and that trans-fatty acids are not produced in non-ruminant animals, but are derived from food (55).

The concentrations of the endogenous PFAMs were relatively low, ranging from 100 \pm 60 pmoles/10^7 cells for linoleamide to 930 \pm 250 pmoles/10^7 cells for palmitamide (Table 2). Upon growth of the N_{18}TG_2 cells in the presence of exogenously added fatty acids (using BSA as a carrier), the corresponding PFAM was identified from both the cells and the N_{18}TG_2 cell-conditioned media (Table 4). Statistical analysis of the PFAM production data to define the robustness of the measured differences in the PFAM levels is included in Tables S1 and S2 (Supplementary Material). In most cases, the amount of PFAM found in the conditioned media was similar to the amount isolated from the washed cells. Incubation of the N_{18}TG_2 cells for 0, 12, 24 or 48 hr in the presence of exogenously added fatty acids leads to continued production of the corresponding PFAM (Table 4, Fig. 2A, and Fig. 2C). Tridecanamide was produced by the N_{18}TG_2 cells from two precursors added to the cell culture medium, tridecanoate and
N-tridecanoyethanolamine (Table 4, Fig. 3A, and Fig. 3C). There is evidence that the NAEs can serve as precursors to the NAGs and the PFAMs (44-46) and this is the first evidence that such chemistry can take place in the N\textsubscript{18}TG\textsubscript{2} cells. Palmitamide was the most abundant PFAM after incubation of the N\textsubscript{18}TG\textsubscript{2} cells with palmitic acid. Palmitoleamide was the next most abundant PFAM, followed by elaidamide, oleamide, linoleamide, and tridecanamide after 48 hr incubation with the corresponding free fatty acid.

**Analysis of PFAMs Produced by the SCP Cells**

Incubation of the SCP cells with each fatty acid lead to the production of corresponding PFAM (Figs. 2B and 2D), including the non-naturally occurring tridecanamide. In most cases, the amount of PFAM found in the conditioned media was similar to the amount of PFAM found in the cells themselves (Table 4), as was seen for N\textsubscript{18}TG\textsubscript{2} cells. The amounts of amides found from the SCP cells and in the SCP conditioned media after 0, 12, 24 or 48 hours incubation with corresponding fatty acids can be found in Table 3 and Figs. 2B and 2D. Overall, higher levels of the PFAMs were identified from the SCP cells and SCP cell-conditioned media relative to those measured for the N\textsubscript{18}TG\textsubscript{2} cells and N\textsubscript{18}TG\textsubscript{2} cell-conditioned media. Note that oleamide was the most abundant PFAM produced by the SCP cells.

As was observed in the N\textsubscript{18}TG\textsubscript{2} cells, we found that tridecanamide was produced by the SCP cells from both tridecanoate and N-tridecanoyethanolamine (Table 4, Fig. 3B, and Fig. 3D). This is the first report of the conversion of an NAE to a PFAM in the SCP cells.

**Controls for the Time-Dependent Production of Oleamide in the N\textsubscript{18}TG\textsubscript{2} and SCP Cells**

To insure that the increasing amounts of the PFAMs we measured over time (Table 4 and Fig. 2) results from the cellular conversion of the exogenously added fatty acid to the PFAM, we carried out a set of control experiments to determine if the observed increases in oleamide vs.
time in the N_{18}TG_{2} cells could be attributed to either (a) reactions independent of the oleic acid added to the culture medium or (b) reactions that occur in the cell culture medium alone.

To test for oleamide production in the cells grown in the absence of exogenously added oleic acid, both N_{18}TG_{2} and SCP cells were incubated for 48 hr with media containing 0.5% FBS and 0.25 mM BSA carrier alone. There was no significant difference between the amount of oleamide found at the time = 0 point (Table 4) and that found in cells incubated for 48 hr with BSA and low serum media only (data not shown).

A set of cell-free controls were run to test for the formation of PFAMs in media. Mueller and Driscoll (56) have identified oleamide-synthesizing activity in FBS, a component of the culture media in used in our experiments. Mueller and Driscoll (56) reported that incubation of oleoyl-CoA and ammonia or glycine in the presence of FBS resulted in the formation of oleamide or N-oleoylglycine, respectively. To test for oleamide-forming activity in the media, cell-free unconditioned and conditioned media were incubated with oleic acid, N-oleoylglycine, or N-oleoylethanolamine for 48 hr. We found no significant difference between the amount of oleamide present in the blank controls and media (both conditioned and unconditioned) exposed to oleoyl metabolites.

**FAAH Expression Studies**

The PFAM levels produced in the SCP cells is generally higher than that found in N_{18}TG_{2} cells (Table 4). One possible explanation for these results would be the lack of expression of FAAH in the SCP cells. FAAH is likely the main enzyme involved in the PFAM degradation *in vivo* (31,32). Western blot analysis and RT-PCR were employed to interrogate FAAH expression in the SCP cells, the N_{18}TG_{2} cells, and human embryonic kidney cells (HEK-293) cells. The N_{18}TG_{2} and HEK-293 cells serve as positive controls as both of the these cell
lines are known to express FAAH (48,57). Both Western analysis (Fig. 4) and RT-PCR (data not included) show FAAH expression in the N18TG2 and HEK-293 cells, but we find no detectable FAAH expression in the SCP cells by either method.

**DISCUSSION**

This is the first report of the conversion of free fatty acids other than oleic acid to their respective PFAMs in N18TG2 cells, and the first finding of the other endogenous PFAMs in N18TG2 cells. Although oleamide is the best studied PFAM, it is only one of many known mammalian PFAMs (3). In addition, this is the first report of the PFAMs being found both endogenously and upon incubation with free fatty acids in SCP cells. Our controls show that the PFAMs produced by the N18TG2 and SCP cells cannot be attributed to contamination or cell-free production by reactions in the culture medium.

There are a few discernible patterns when comparing the PFAM quantification data from or between the two cell lines. In general, the levels of the endogenous PFAMs are higher in the SCP cells. This is most evident for oleamide, for which the endogenous level in the SCP cells is ~50-fold higher than in the N18TG2 cells (6400 pmoles per 10^7 cells vs. 120 pmoles per 10^7 cells, see Table 2). The endogenous PFAM levels reflect a steady-state balance between production, degradation, and secretion, and are also likely influenced by the fatty acids and other fatty acid-containing moieties of the growth medium.

As was observed with the endogenous PFAM levels, there are a few obvious patterns in comparing PFAM production data (in cells and excreted into the media) in the two cell lines. Similar to the endogenous PFAM levels, total PFAM production is generally higher for the SCP cells, ranging from ~4-fold higher for tridecanamide to ~40-fold for linoleamide. Palmitoleamide and palmitamide are exceptions with ~2-fold higher amounts produced by the
N18TG2 cells relative to the SCP cells. In comparing the amounts of the specific PFAMs that were produced, the elaidamide levels were consistently higher than the oleamide levels and tridecanamide was always the lowest in the two cell lines (whether produced from the tridecanoate or N-tridecanoyl ethanolamine). One likely reason for the higher levels of total PFAM production in the SCP cells is the lack of detectable FAAH expression in these cells (Fig. 4 and ref. 58). These data and higher endogenous PFAM levels in the SCP cells (Table 2) are consistent with published results showing that FAAH is the major enzyme involved in PFAM degradation (31,32). In fact, the relative endogenous levels of the PFAMs and the steady-state PFAM levels at 48 hr in the N18TG2 cells are a reasonable match for the substrate preferences for FAAH (59-62); the PFAMs with a relatively high V_MAX/K_M value are found in lower amounts, suggesting the FAAH is the dominant PFAM degradative enzyme in these cells.

Since elaidamide is a non-natural PFAM, elaidamide might be a relatively poor substrate for FAAH and other pathways for PFAM degradation. This could explain the high abundance of elaidamide relative to oleamide after incubation with the corresponding fatty acid. Similarly, tridecanoate is a non-natural fatty acid and might be a relatively poor substrate for the enzyme(s) of PFAM biosynthesis accounting for the relatively low abundance of tridecanamide. In vitro data on the PAM-catalyzed oxidation of N-fatty acylglycines to the corresponding PFAMs show a preference for longer acyl chain substrates (34,35). The higher PFAM12/PFAM48 ratio in the N18TG2 cells relative to the SCP reflects a greater net rate of net PFAM biosynthesis in the N18TG2 cells, a lower net rate of PFAM degradation in the N18TG2 cells, or a combination of both. Given the current uncertainties in the pathways for the biosynthesis and degradation of the PFAMs and the transport mechanism into and out of cells, definitive conclusions about the relative abundances of the PFAMs in the N18TG2 and SCP cells are not possible. The data
presented here provide key information to evaluate models of PFAM flux as the PFAM biosynthetic and degradative pathways are better defined.

In addition to testing for the conversion of endogenously found fatty acids to their respective primary amides, a non-natural fatty acid, tridecanoate, and its corresponding NAE were also incubated with the cells to test for their conversion to a PFAM. These experiments were to demonstrate that a model fatty acid with a non-naturally occurring acyl chain could serve as a substrate for PFAM biosynthesis, to determine if NAEs could also serve as PFAM substrates in these cells, and to compare the flux of an NAE and its corresponding FFA to PFAM. *In vitro* data and data from other cells have suggested that NAEs are precursors to the PFAMs (44-46,63). Our hypothesis was that the non-naturally occurring N-tridecanoylethanolamine would be a relatively poor FAAH substrate and, thus, result in greater accumulation of tridecanamide. We identified and quantified tridecanamide in the model cell lines after incubation with N-tridecanoylethanolamine (Fig. 3). This is the first report of the conversion of an NAE to the corresponding PFAM in the N_{18}TG_{2} and SCP cells, providing additional evidence for the NAEs serving as precursors to the PFAMs. The levels of tridecanamide produced from N-tridecanoylethanolamine were higher than that produced by tridecanoate in the SCP cells. The differences in overall production of tridecanamide between the SCP and N_{18}TG_{2} cells could result from differences in the rates of tridecanoate being converted into phospholipids in the two cells. Nonetheless, it is intriguing that the SCP cells, which do not express FAAH (Fig. 4), produce a higher level of tridecanamide suggesting that FAAH plays a major role in the cellular degradation of the NAEs.

In conclusion, five endogenous PFAMs were found in N_{18}TG_{2} and SCP cells, all of which are new findings (except for oleamide in N_{18}TG_{2}). The amount of endogenous PFAMs
was much higher in the SCP cells, particularly for oleamide. These data indicate the focus on oleamide within the field of primary fatty acid amides can and should be broadened to other members of this class of fatty acid amides. After incubation with the corresponding fatty acid, PFAMs could be found in both cells and conditioned media, and the profile of PFAM levels was different between the two cell lines. The data presented here provide strong support for the role of FAAH as the major enzyme of PFAM degradation \textit{in vivo}, demonstrate that the N\textsubscript{18}TG\textsubscript{2} cells are a good model system for the study of PFAM metabolism, show that SCP cells are an important FAAH-independent model for the study of PFAM metabolism, support a role for the NAEs as PFAM precursors, and provide useful kinetic results for modeling the metabolic flux through the pathways of PFAM biosynthesis and degradation.
ACKNOWLEDGEMENTS

This work was supported, in part, by grants from the National Institutes of Health - General Medical Sciences (R15-GM059050), the Florida Center for Excellence for Biomolecular Identification and Targeted Therapeutics (FCoE-BITT grant no. GALS020), the Shirley W. and William L. Griffin Foundation, the Gustavus and Louise Pfeiffer Research Foundation, the Wendy Will Case Cancer Fund, the Milheim Foundation for Cancer Research, the Eppley Foundation for Research, and the Alpha Research Foundation, Inc. to D.J.M. and a Graduate Multidisciplinary Scholars (GMS) award through the USF Thrust Life Sciences Program administered by the Florida Center of Excellence for Biomolecular Identification and Targeted Therapeutics to E.K.F. The authors would like to thank Milena Ivkovic for synthesizing the N-tridecanoyl ethanolamine, Lamar Galloway for technical assistance, and Jeremy Gibson for assistance with the statistical analysis of our data. The authors dedicate this work to the memory of Dr. Mitchell E. Johnson.
REFERENCES


**Figure Legends**

**Figure 1.** Proposed Pathways for the Biosynthesis and Degradation of the N-Fatty Acylglycines and the PFAMs. Other possible biosynthetic and degradative reactions are discussed in the review by Farrell and Merkler (29). Abbreviations are as follows: ASC is ascorbate, Cytc is cytochrome c, FAAH is fatty acid amide hydrolase, fADH is fatty alcohol dehydrogenase, fAldDH is fatty aldehyde dehydrogenase, GLYAT is glycine N-acyltransferase, PAM is peptidylglycine α-amidating monooxygenase, PFAM is primary fatty acid amide, and SDA is semidehydroascorbate.

**Figure 2.** PFAMs Produced in N\textsubscript{18}TG\textsubscript{2} and SCP Cells Incubated with the Indicated Fatty Acids. Data here is only for the amount of the PFAMs extracted from the N\textsubscript{18}TG\textsubscript{2} and SCP cells after the indicated incubation time. The data for the PFAMs from the cell conditioned media is in Table 4. Panel A shows amount of PFAM isolated from N\textsubscript{18}TG\textsubscript{2} cells and panel B that from SCP cells. Panels C and D were included to better show the PFAM produced at lower levels in the N\textsubscript{18}TG\textsubscript{2} and SCP cells.

**Figure 3.** Tridecanamide Produced in N\textsubscript{18}TG\textsubscript{2} and SCP Cells from N-Tridecanoylethanolamine. The amount of tridecamide found in cells (black) and excreted into media (gray) is shown. The production of tridecanamide from tridecanoate is in Panel A (from the N\textsubscript{18}TG\textsubscript{2} cells) and Panel B (from the SCP cells). The production of tridecanamide from N-tridecanoylethanolamine is in Panel C (from the N\textsubscript{18}TG\textsubscript{2} cells) and Panel D (from the SCP cells).
Figure 4. FAAH Expression via Western Analysis. Lanes are as follows: 1-2 are from the HEK-293 cells, 3-5 are from the N_{18}TG_{2} cells, 6 is an empty lane, and 7-8 are from the SCP cells.
<table>
<thead>
<tr>
<th>Compound</th>
<th>Selected m/z Values</th>
<th>Retention Time (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>[^{3} \text{H}_{33}]-Heptadecanoic acid</td>
<td>119, 135, 149, 360, 375</td>
<td>15.1</td>
</tr>
<tr>
<td>Tridecanonitrile</td>
<td>82, 97, 110, 124, 138, 147, 152, 166, 170, 188, 192, 195</td>
<td>9</td>
</tr>
<tr>
<td>Tridecanamide-TMS</td>
<td>93, 100, 128, 131, 158, 170, 186, 200, 213, 270, 285</td>
<td>13.4</td>
</tr>
<tr>
<td>Palmitoleonitrile</td>
<td>122, 136, 150, 164, 178, 192, 206, 235</td>
<td>12.66</td>
</tr>
<tr>
<td>Palmitoleamide-TMS</td>
<td>59, 116, 128, 131, 144, 184, 198, 200, 240, 253, 310, 325</td>
<td>16.07</td>
</tr>
<tr>
<td>Palmitonitrile(^a)</td>
<td>69, 110, 124, 138, 152, 166, 180, 194, 208, 237, 95, 109, 120, 134, 148, 162, 176, 261</td>
<td>12.9</td>
</tr>
<tr>
<td>Linoleonitrile(^b)</td>
<td>59, 67, 81, 91, 95, 109, 116, 119, 121, 128, 131, 135, 144, 147, 149, 336, 352, 279</td>
<td>14.8</td>
</tr>
<tr>
<td>Linoleamide-TMS</td>
<td>83, 97, 110, 122, 136, 150, 164, 190, 206, 220, 234, 263</td>
<td>14.9</td>
</tr>
</tbody>
</table>

\(^a\)Palmitamide-TMS was not integrated due to interference of relatively high amounts of oleic acid-TMS and octadecanoic acid-TMS that interfered with the selected ion integration. Amounts of palmitamide were determined based on the palmitonitrile only, using standard curves of palmitonitrile only.

\(^b\)Linoleamide-TMS was not integrated for a similar reason as for palmitamide-TMS, and only linoleonitrile was integrated, using standard curves of linoleonitrile only.
**Table 2.**

Endogenous PFAM Levels in the N18TG2 and SCP Cells\(^a\)

<table>
<thead>
<tr>
<th>PFAM</th>
<th>N18TG2 Cells (pmoles/10^7 cells)</th>
<th>SCP Cells (pmoles/10^7 cells)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palmitoleamide</td>
<td>340 ± 110</td>
<td>410 ± 50</td>
</tr>
<tr>
<td>Palmitamide</td>
<td>930 ± 250</td>
<td>1200 ± 210</td>
</tr>
<tr>
<td>Oleamide</td>
<td>120 ± 50</td>
<td>6400 ± 2300</td>
</tr>
<tr>
<td>Linoleamide</td>
<td>100 ± 60</td>
<td>250 ± 180</td>
</tr>
</tbody>
</table>

\(^a\)The PFAM amounts are reported as the average ± standard deviation for 3 determinations.


**Table 3.**
Background PFAM Levels from the Solvents and Plasticware^{a,b}

<table>
<thead>
<tr>
<th>PFAM</th>
<th>Background Amount for N_{18}TG_{2} Cells (pmole/10^7 cells)</th>
<th>Background Amount for SCP Cells (pmole/10^7 cells)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palmitoleamide</td>
<td>23 ± 7.0</td>
<td>140 ± 46</td>
</tr>
<tr>
<td>Palmitamide</td>
<td>12 ± 2.3</td>
<td>76 ± 15</td>
</tr>
<tr>
<td>Oleamide^c</td>
<td>8.7 ± 4.1</td>
<td>55 ± 26</td>
</tr>
<tr>
<td>Linoleamide</td>
<td>14 ± 6.5</td>
<td>89 ± 41</td>
</tr>
<tr>
<td>Tridecanamide</td>
<td>17 ± 19</td>
<td>410 ± 450</td>
</tr>
</tbody>
</table>

^{a}To facilitate comparison of these data to the cellular production data, the moles of amide found in these blanks was divided by an average number of viable cells (1.24 × 10^7 for SCP or 7.9 × 10^7 for N_{18}TG_{2}).

^{b}The PFAM amounts are reported as the average ± standard deviation for 4 determinations.

^{c}This value actually represents the sum of the background levels of oleamide and elaidamide.

Background levels of elaidamide (*trans*-9-octadecenic acid) are most likely ~0 (51,53).
Table 4

PFAMs in Cells and Media\(^{a,b}\)

<table>
<thead>
<tr>
<th>PFAM origin</th>
<th>SCP cells</th>
<th>SCP media</th>
<th>N(_{18})TG(_2) cells</th>
<th>N(_{18})TG(_2) media</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tridecanoic acid</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 hr</td>
<td>2.0 ± 0.31</td>
<td>2.2 ± 0.92</td>
<td>0.10 ± 0.010</td>
<td>0.28 ± 0.23</td>
</tr>
<tr>
<td>24 hr</td>
<td>2.7 ± 0.75</td>
<td>3.2 ± 1.2</td>
<td>0.26 ± 0.12</td>
<td>0.50 ± 0.16</td>
</tr>
<tr>
<td>48 hr</td>
<td>2.3 ± 0.30</td>
<td>5.1 ± 0.43</td>
<td>0.75 ± 0.32</td>
<td>1.3 ± 0.37</td>
</tr>
<tr>
<td>N-Tridecanoylethanolamine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 hr</td>
<td>1.1 ± 0.28</td>
<td>2.0 ± 1.4</td>
<td>0.14 ± 0.068</td>
<td>0.26 ± 0.21</td>
</tr>
<tr>
<td>24 hr</td>
<td>2.7 ± 0.36</td>
<td>7.5 ± 1.6</td>
<td>0.28 ± 0.16</td>
<td>0.45 ± 0.037</td>
</tr>
<tr>
<td>48 hr</td>
<td>6.6 ± 1.5</td>
<td>10 ± 1.1</td>
<td>0.57 ± 0.27</td>
<td>1.0 ± 0.49</td>
</tr>
<tr>
<td>Palmitoleic acid</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 hr</td>
<td>2.0 ± 0.36</td>
<td>3.8 ± 0.35</td>
<td>1.0 ± 0.77</td>
<td>1.9 ± 1.6</td>
</tr>
<tr>
<td>24 hr</td>
<td>3.1 ± 1.8</td>
<td>5.4 ± 2.1</td>
<td>5.8</td>
<td>8.5</td>
</tr>
<tr>
<td>48 hr</td>
<td>2.9 ± 1.6</td>
<td>7.9 ± 0.76</td>
<td>8.3 ± 1.3</td>
<td>15</td>
</tr>
<tr>
<td>Palmitic acid</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 hr</td>
<td>3.7 ± 0.79</td>
<td>5.3 ± 1.4</td>
<td>6.2 ± 1.8</td>
<td>2.2 ± 1.0</td>
</tr>
<tr>
<td>24 hr</td>
<td>4.5 ± 1.6</td>
<td>6.4 ± 0.74</td>
<td>8.7 ± 3.7</td>
<td>21 ± 8.2</td>
</tr>
<tr>
<td>48 hr</td>
<td>33 ± 3.0</td>
<td>25 ± 8.4</td>
<td>21 ± 6.7</td>
<td>74 ± 27</td>
</tr>
<tr>
<td>Oleic acid</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 hr</td>
<td>6.8</td>
<td>5.7 ± 3.7</td>
<td>0.82 ± 0.27</td>
<td>0.78 ± 0.32</td>
</tr>
<tr>
<td>24 hr</td>
<td>9.8 ± 2.9</td>
<td>17 ± 2.1</td>
<td>2.1 ± 0.71</td>
<td>1.4 ± 0.20</td>
</tr>
<tr>
<td>48 hr</td>
<td>10 ± 5.8</td>
<td>13 ± 3.9</td>
<td>2.1 ± 0.42</td>
<td>1.7 ± 0.13</td>
</tr>
<tr>
<td>Elaidic acid</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 hr</td>
<td>12 ± 3.1</td>
<td>17</td>
<td>0.74 ± 0.20</td>
<td>1.7 ± 0.20</td>
</tr>
<tr>
<td>24 hr</td>
<td>21</td>
<td>51 ± 19</td>
<td>1.4 ± 0.32</td>
<td>1.9 ± 0.59</td>
</tr>
<tr>
<td>48 hr</td>
<td>21 ± 7.2</td>
<td>130 ± 19</td>
<td>6.7 ± 2.2</td>
<td>11 ± 0.74</td>
</tr>
<tr>
<td>Linoleic acid</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 hr</td>
<td>4.0 ± 1.3</td>
<td>7.0 ± 1.7</td>
<td>0.35 ± 0.16</td>
<td>0.39 ± 0.044</td>
</tr>
<tr>
<td>24 hr</td>
<td>5.2 ± 0.73</td>
<td>26 ± 8.1</td>
<td>0.30 ± 0.12</td>
<td>0.41 ± 0.11</td>
</tr>
<tr>
<td>48 hr</td>
<td>29 ± 10</td>
<td>54 ± 30</td>
<td>1.3 ± 0.37</td>
<td>0.85 ± 0.27</td>
</tr>
</tbody>
</table>

\(^{a}\)The amounts are reported as nmoles/10\(^7\) cells and are the average ± standard deviation for two to three determinations. In a few instances, only a single determination was made. In a few instances, only a single determination was made.

\(^{b}\)Blank values have been subtracted from the amounts found in experimental samples prior to reporting here: solvent blank for the cell samples and unconditioned media blank for the media samples.
**Figure 1.**

**Cyto c**

\[ \text{NH}_3 \rightarrow \text{CoA-SH} \]

**Cyto c/GLYAT**

- Acyl-CoA \[ \rightarrow \text{CoA-SH} \rightarrow \text{Glycine} \]
- \( \text{N-Acylglycine} \)

**PAM**

- \( \text{Glyoxylate} \rightarrow O_2 + H_2O \)
- \( 2\text{ASC} + 2\text{SDA} \)

**fAldDH/fADH**

- \( \text{NADH} \rightarrow \text{NAD}^+ \)

**fADH**

- \( \text{NADH} \rightarrow \text{NAD}^+ \)

**FAAH**

- \( \text{Ethanolamine} \rightarrow \text{H}_2\text{O} \)

**Cyto c**

- \( \text{H}_2\text{O} \rightarrow \text{NH}_3 \)

**N-Acylglycinal**

**NAE**
**FIGURE 2.**

A. \(N_{18}\)TG\(_2\) Cells
- TDA (from fatty acid)
- TDA (from NAE)
- Linoleamide
- Oleamide
- Elaidamide
- Palmitoleamide
- Palmitamide

B. SCP Cells
- TDA (from fatty acid)
- Linoleamide
- Oleamide
- Palmitoleamide
- Palmitoleamide
- Palmitoleamide

C. \(N_{18}\)TG\(_2\) Cells (Expanded)
- TDA (from fatty acid)
- TDA (from NAE)
- Linoleamide
- Oleamide

D. SCP (Expanded)
- TDA (from fatty acid)
- TDA (from NAE)
- Linoleamide
- Palmitoleamide
FIGURE 3.

Panels A & B: Tridecanamide Produced from Tridecanoic Acid

A. N18TG2 Cells
- Extracted from cells
- Extracted from conditioned media

B. SCP Cells
- Extracted from cells
- Extracted from conditioned media

Panels C & D: Tridecanamide Produced from N-Trimdecanoylethanolamine

C. N18TG2 Cells
- Extracted from cells
- Extracted from conditioned media

D. SCP Cells
- Extracted from cells
- Extracted from conditioned media
Figure 4.